Singapore: United States Patent Office has issued official "Letters Patent" on a key patent in the PAT-LM1 family; US patent 8,562,995 entitled "Neoplasm specific antibodies and uses thereof".
This is the second patent to be granted in the US jurisdiction, and the third for the PAT-LM1 family. In June this year a patent covering the use of the PAT-LM1 antibody or binding fragments for the treatment or prevention of metastasis was granted in New Zealand.
The patent claims the PAT-LM1 antibody and other variants comprising the Complementary Determining Region (CDRs) of the PAT-LM1 antibody.
"This patent expands our intellectual property position and protects our lead product PAT-LM1. The US is a major strategic jurisdiction for therapeutic antibodies. The granting of three patents in the PAT-LM1 family further increases the value of Patrys' patent assets, especially in the field of oncology", said Dr. Marie Roskrow, Patrys' Chief Executive Officer.
